Tag: Miltefosine

Over 12 million people are infected with leishmaniasis worldwide, a disease caused by more than 20 *Leishmania* species. A single, universal regimen is not possible, as the question of **what is the drug of choice for all forms of leishmaniasis** depends on the specific clinical manifestation and geographic location of the infection.

With an estimated 350 million people worldwide at risk, leishmaniasis is a serious parasitic disease that can manifest in various forms. The development of effective oral treatments, such as the Impavido treatment (miltefosine), has significantly improved patient care for this often-neglected tropical disease.

Leishmaniasis affects an estimated 12 million people worldwide in 98 countries, making it a significant global health concern. In the United States, the Food and Drug Administration (FDA) has approved specific treatments for different forms of this parasitic disease, answering the question: 'What is the FDA approved treatment for leishmaniasis?'.

Originally developed as an anti-cancer agent, miltefosine was later repurposed to treat leishmaniasis, a parasitic disease. The answer to **What is the generic for miltefosine?** is that miltefosine itself is the generic name for this medication, which is sold under the brand name Impavido.

Miltefosine, the only oral treatment for leishmaniasis, was originally developed as an anticancer agent before being repurposed for parasitic diseases. Knowing how to obtain miltefosine requires navigating a specific set of procedures, including securing a medical prescription, understanding commercial availability, and adhering to strict safety protocols.

Leishmaniasis, a parasitic disease spread by sand fly bites, affects up to 12 million people worldwide. So, **what is Impavido used for?** It is the first and only FDA-approved oral medication for treating specific forms of this challenging disease.

With an estimated 0.7 to 1 million new cases annually, leishmaniasis is a significant global health issue. So, what does Impavido treat? This oral medication is a primary weapon against specific parasitic infections caused by the *Leishmania* parasite and is also used for other rare but deadly infections.

Leishmaniasis is classified as a neglected tropical disease by the World Health Organization and is the second-leading parasitic killer globally, after malaria. The strategy of drug repurposing—the process of finding new uses for existing drugs—is providing a critical, cost-effective pathway to identify novel treatments for this parasitic infection.

Originally developed as an anticancer agent, miltefosine later emerged as the world's first effective oral drug for leishmaniasis, a neglected tropical disease. This was a significant breakthrough, offering a convenient alternative to traditional parenteral treatments for visceral leishmaniasis (VL). The drug, sold under the brand name Impavido in some regions, has demonstrated high cure rates, though its efficacy can vary by geographic location and parasite species.

Leishmaniasis is a parasitic disease estimated to affect hundreds of thousands of people annually worldwide, with a historical reliance on injectable treatments. The development of miltefosine, the first and only recognized oral drug for leishmaniasis, marked a significant advancement in therapeutic options for this neglected tropical disease.